Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Change in Lymphocyte T CD4+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD3+/CD4+ |
Month 3 |
|
Primary |
Change in T helper1 (Th1) Lymphocyte T CD4+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+ /CCR6- |
Month 3 |
|
Primary |
Change in Th1*Lymphocyte T CD4+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+/CCR+ |
Month 3 |
|
Primary |
Change in naive Lymphocyte T CD4+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7+ |
Month 3 |
|
Primary |
Change in effector memory Lymphocyte T CD4+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7- |
Month 3 |
|
Primary |
Change in central memory Lymphocyte T CD4+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7+ |
Month 3 |
|
Primary |
Change in Teffector memory RA+ Lymphocyte T CD4+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7- |
Month 3 |
|
Primary |
Change in FOXP3 Treg / Treg Lymphocyte T CD4+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD25+/CD127+/FOXP3+ |
Month 3 |
|
Primary |
Change in naive Treg Lymphocyte T CD4+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/FOXP3+ |
Month 3 |
|
Primary |
Change in memory Treg Lymphocyte T CD4+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/FOXP3+ |
Month 3 |
|
Primary |
Change in Tr1 Lymphocyte T cells CD4+ since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD49b+/LAG3+ |
Month 3 |
|
Primary |
Change in Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD3+/CD4- |
Month 3 |
|
Primary |
Change in naive Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7+ |
Month 3 |
|
Primary |
Change in effector memory Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7- |
Month 3 |
|
Primary |
Change in central memory Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/CCR7+ |
Month 3 |
|
Primary |
Change in Teffector memory RA+ Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/CCR7- |
Month 3 |
|
Primary |
Change in Tc1 Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+/CCR6- |
Month 3 |
|
Primary |
Change in Tc1* Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3+/CCR6+ |
Month 3 |
|
Primary |
Change in Tc2 Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3-/CCR6- |
Month 3 |
|
Primary |
Change in Tc17 Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CXCR3-/CCR6+ |
Month 3 |
|
Primary |
Change in CD8 Tcreg / TcReg Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD25+/CD127+/FOXP3+ |
Month 3 |
|
Primary |
Change in naive Tcreg Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA+/FOXP3+ |
Month 3 |
|
Primary |
Change in memory Tcreg Lymphocyte T CD8+ cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD45RA-/FOXP3+ |
Month 3 |
|
Primary |
Change in Lymphocyte B cells since baseline |
Percentage variation measured by Fluorescence Activated Cell Sorting of cells CD19+ |
Month 3 |
|
Secondary |
lymphocyte subpopulations change in CD6 phenotype after 3 months of high dose vitamin D treatment or placebo |
Measured by Fluorescence Activated Cell Sorting of cells |
Month 3 |
|
Secondary |
lymphocyte subpopulations change in CD162 phenotype after 3 months of high dose vitamin D treatment or placebo |
Measured by Fluorescence Activated Cell Sorting of cells |
Month 3 |
|
Secondary |
lymphocyte subpopulations change in CD226 phenotype after 3 months of high dose vitamin D treatment or placebo |
Measured by Fluorescence Activated Cell Sorting of cells |
Month 3 |
|
Secondary |
lymphocyte subpopulations change in CD46 phenotype after 3 months of high dose vitamin D treatment or placebo |
Measured by Fluorescence Activated Cell Sorting of cells |
Month 3 |
|
Secondary |
lymphocyte subpopulations change in CD11a phenotype after 3 months of high dose vitamin D treatment or placebo |
Measured by Fluorescence Activated Cell Sorting of cells |
Month 3 |
|
Secondary |
lymphocyte subpopulations change in CD49d phenotype after 3 months of high dose vitamin D treatment or placebo |
Measured by Fluorescence Activated Cell Sorting of cells |
Month 3 |
|
Secondary |
lymphocyte subpopulations change in CLA phenotype after 3 months of high dose vitamin D treatment or placebo |
Measured by Fluorescence Activated Cell Sorting of cells |
Month 3 |
|
Secondary |
Change in production of cytokine IL-10 in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo |
Measured by Fluorescence Activated Cell Sorting of cells |
Month 3 |
|
Secondary |
Change in production of cytokine IFNg in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo |
Measured by Fluorescence Activated Cell Sorting of cells |
Month 3 |
|
Secondary |
Change in production of cytokine IL-17 in lymphocyte subpopulations after 3 months of high dose vitamin D treatment or placebo |
Measured by Fluorescence Activated Cell Sorting of cells |
Month 3 |
|
Secondary |
Change in plasma Vitamin D levels 3 months after baseline of high dose Vitamin D treatment versus placebo |
Determination of 25-OH-D2 and 25-OH-D3 forms in nmol/L in plasma with the "vitamin D total II" kit |
Month 3 |
|
Secondary |
Change in 16sRNA levels 3 months after baseline of high dose Vitamin D treatment versus placebo |
|
Month 3 |
|
Secondary |
Nature of gut microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo |
Number of operational taxonomic units |
Month 3 |
|
Secondary |
Nature of blood microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo |
Number of operational taxonomic units |
Month 3 |
|
Secondary |
Percentage of gut microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo |
Percentage of operational taxonomic units |
Month 3 |
|
Secondary |
Percentage of blood microbiota taxonomy 3 months after high dose Vitamin D treatment versus placebo |
Percentage of operational taxonomic units |
Month 3 |
|
Secondary |
Diversity of gut microbiota 3 months after high dose Vitamin D treatment versus placebo |
Shannon index |
Month 3 |
|
Secondary |
Diversity of blood microbiota 3 months after high dose Vitamin D treatment versus placebo |
Shannon index |
Month 3 |
|
Secondary |
Beta diversity of gut microbiota 3 months after high dose Vitamin D treatment versus placebo |
Bray-Curtis index |
Month 3 |
|
Secondary |
Beta diversity of blood microbiota 3 months after high dose Vitamin D treatment versus placebo |
Bray-Curtis index |
Month 3 |
|
Secondary |
Describing the genetic determinants of vitamin D response using a Single Nucleotide Polymorphism (SNP) database |
Description of individual SNPs |
Month 3 |
|